Cargando…

PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease

BACKGROUND: We previously demonstrated that subcutaneous administration of PT320, a sustained-release (SR) form of exendin-4, resulted in the long-term maintenance of steady-state exenatide (exendin-4) plasma and target levels in 6-hydroxydopamine (6-OHDA)-pretreated animals. Additionally, pre- or p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Seong-Jin, Chen, Shuchun, Yang, Yung-Yung, Glotfelty, Elliot J., Jung, Jin, Kim, Hee Kyung, Choi, Ho-Il, Choi, Doo-Sup, Hoffer, Barry J., Greig, Nigel H., Wang, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431885/ https://www.ncbi.nlm.nih.gov/pubmed/32848559 http://dx.doi.org/10.3389/fnins.2020.00785

Ejemplares similares

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
por: Chen, Shuchun, et al.
Publicado: (2018)

Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
por: Chen, Shuchun, et al.
Publicado: (2018)

PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease
por: Kuo, Tung-Tai, et al.
Publicado: (2023)

The Role of the Subthalamic Nucleus in L-DOPA Induced Dyskinesia in 6-Hydroxydopamine Lesioned Rats
por: Aristieta, Asier, et al.
Publicado: (2012)

Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
por: Shin, Keon Sung, et al.
Publicado: (2015)

Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats
por: Eakin, Katharine, et al.
Publicado: (2013)

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats
por: Wang, Wen-Wen, et al.
Publicado: (2019)

Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
por: Li, Yazhou, et al.
Publicado: (2019)

Targeting the D1-N-methyl-d-aspartate receptor complex reduces l-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Song, Lu, et al.
Publicado: (2016)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

Propranolol Relieves L-Dopa-Induced Dyskinesia in Parkinsonian Mice
por: Shi, Ziqing, et al.
Publicado: (2020)

Opioid system in L-DOPA-induced dyskinesia
por: Pan, Jing, et al.
Publicado: (2017)

Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia
por: Wang, Qiang, et al.
Publicado: (2016)

On the neuronal circuitry mediating l-DOPA-induced dyskinesia
por: Cenci, M. Angela, et al.
Publicado: (2018)

Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease
por: Athulya, RT, et al.
Publicado: (2020)

Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)
por: Yang, Kai, et al.
Publicado: (2021)

Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia
por: Ghiglieri, Veronica, et al.
Publicado: (2012)

Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia
por: Fabbrini, Andrea, et al.
Publicado: (2021)

(−)‐Phenserine tartrate (PhenT) as a treatment for traumatic brain injury
por: Greig, Nigel H., et al.
Publicado: (2019)

L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum
por: Porras, Gregory, et al.
Publicado: (2014)

Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?
por: Rylander Ottosson, Daniella, et al.
Publicado: (2016)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia
por: Bastide, Matthieu F., et al.
Publicado: (2017)

Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
por: Navailles, Sylvia, et al.
Publicado: (2012)

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
por: Cenci, M. Angela
Publicado: (2014)

L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson’s Disease
por: Blosser, Joshua A., et al.
Publicado: (2020)

The Vasomotor Response to Dopamine Is Altered in the Rat Model of l‐dopa‐Induced Dyskinesia
por: Booth, Samuel, et al.
Publicado: (2020)

Eltoprazine modulated gamma oscillations on ameliorating L‐dopa‐induced dyskinesia in rats
por: Bi, Yuewei, et al.
Publicado: (2023)

Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA–induced dyskinesia
por: Fridjonsdottir, Elva, et al.
Publicado: (2021)

Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model
por: Kambey, Piniel Alphayo, et al.
Publicado: (2023)

Untangling Cortico-Striatal Connectivity and Cross-Frequency Coupling in L-DOPA-Induced Dyskinesia
por: Belić, Jovana J., et al.
Publicado: (2016)

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
por: Comi, Cristoforo, et al.
Publicado: (2017)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
por: Lanza, Kathryn, et al.
Publicado: (2021)

Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia
por: Hulme, Heather, et al.
Publicado: (2022)

Phosphodiesterase 10A Inhibition Modulates the Corticostriatal Activity and L-DOPA-Induced Dyskinesia
por: Guimarães, Rayanne Poletti, et al.
Publicado: (2022)

7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate
por: Herrero, M. T., et al.
Publicado: (2023)

Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
por: Sano, Hiromi, et al.
Publicado: (2023)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

β-Lapachone ameliorates L-DOPA-induced dyskinesia in a 6-OHDA-induced mouse model of Parkinson's disease
por: Ryu, Young-Kyoung, et al.
Publicado: (2021)

Ginsenoside Re Mitigates 6-Hydroxydopamine-Induced Oxidative Stress through Upregulation of GPX4
por: Lee, Gyeong Hee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ia3emn2q1ol0eak2l7fso7k5p